Results from Lundbeck's open-label portion of the Pacific trial saw bexicaserin able to elicit seizure reduction in treatment ...

Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the 'Abeta Targeting Therapies in AD' symposium on 3 April, Roche presented interim trial data for ...

Beigene has chosen to scrap ociperlimab after analysis found the lung cancer drug wouldn't its endpoint in extending overall survival.